Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12^*

References

• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümpe L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–842.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mournier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten WL, van't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008; 111:537–543.
   PubMed Web of Science ®Google Scholar
• Arnold C, Cuthbert R, Morris TCM, et al. Rituximab-ESHAP as salvage therapy in relapsed aggressive B cell lymphoma. Haematologica. 2005;90:abstract 1146.
   Google Scholar
• Aydin S, Duhrsen U, Nuckel H. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients. Ann Hematol. 2007;86:271–276.
   PubMed Web of Science ®Google Scholar
• Bieker R, Kessler T, Berdel WE, et al. Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma. Oncol Rep. 2003;10:1915–1917.
   PubMed Web of Science ®Google Scholar
• Hicks L, Buckstein R, Mangel J, et al. Rituximab increases response to ESHAP in relapsed, refractory, and transformed aggressive B-cell lymphoma. Blood. 2006;108:abstract 3067.
   Web of Science ®Google Scholar
• Herishanu Y, Terstman S, Perri C, et al. The combination of rituximab, etoposide, ifosfamide and carboplatin (RICE) is safe and effective salvage therapy for elderly patients with aggressive non-Hodkgin’s lymphoma. Haematologica. 2005;90:Abstract 999.
   Google Scholar
• Kewarlarmani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Obrtlikova PO, Vackova B, Pytlik R, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem cell transplantation for diffuse large B-cell lymphoma. Haemotologica. 2006;91:abstract 217.
   Google Scholar
• Panovska-Stavridis I, Georgievski B, Cevreska L, et al. Rituximab plus ICE regimen for relapsed and refractory aggressive non-Hodgkin lymphomas. Haematologica. 2004;89:abstract 763.
   Google Scholar
• Mey UJM, Olivieri A, Orlopp KS, et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma. 2006;47:2558–2566.
   PubMed Web of Science ®Google Scholar
• Sirochi B, Cunningham D, Norman A, et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). Hematology. 2007;12:149–153.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490–3496.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Hay AE, Crump M, et al. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12. J Natl Cancer Inst. 2015;107:djv106.
   PubMedGoogle Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas: NCI-Sponsored International Working Group. J Clin Oncol. 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998;16:3264–3269.
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Czuczman MS, Rodriguez MA, et al. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 2013;122:499–506.
   PubMed Web of Science ®Google Scholar
• van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the Orcharrd Study (OMB110928). Blood. 2014;124:630.
   Web of Science ®Google Scholar